References
- Branford S, Rudzki Z, Walsh S, et al (2003). Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102:276–83
- Cortes JE, Digumarti R, Parikh PM, et al (2013a). Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol 88:350–4
- Cortes JE, Kantarjian HM, Rea D, et al (2015). Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: results with 24 months of follow-up. Cancer 121:1637–44
- Cortes JE, Nicolini FE, Wetzler M, et al (2013b). Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk 13:584–91
- Deininger MW, Goldman JM, Melo JV. (2000). The molecular biology of chronic myeloid leukemia. Blood 96:3343–56
- Dubbelman AC, Rosing H, Schellens JH, Beijnen JH. (2011). Bioanalytical aspects of clinical mass balance studies in oncology. Bioanalysis 3:2637–55
- Fresno M, Jimenez A, Vazquez D. (1977). Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 72:323–30
- Huang MT. (1975). Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 11:511–19
- ICH (2008). Topic M 3 (R2), Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002941.pdf [last accessed 20 Aug 2015]
- Kantarjian HM, Talpaz M, Giles F, et al (2006). New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145:913–23
- Lu K, Savaraj N, Feun LG, et al (1988). Pharmacokinetics of homoharringtonine in dogs. Cancer Chemother Pharmacol 21:139–42
- Nemunaitis J, Mita A, Stephenson J, et al (2013). Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemother Pharmacol 71:35–41
- Ni D, Ho DH, Vijjeswarapu M, et al (2003). Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia. J Exp Ther Oncol 3:47–52
- Nicolini FE, Khoury HJ, Akard L, et al (2013). Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica 98:e78–9
- Penner N, Klunk LJ, Prakash C. (2009). Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos 30:185–203
- Quintas-Cardama A, Cortes J. (2009). Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:1619–30
- Savaraj N, Lu K, Dimery I, et al (1986). Clinical pharmacology of homoharringtonine. Cancer Treat Rep 70:1403–7
- Shah NP, Nicoll JM, Nagar B, et al (2002). Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117–25
- Soverini S, Colarossi S, Gnani A, et al (2006). Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12:7374–9
- US Food and Drug Administration (2008). FDA Guidance for Industry: Safety Testing for Drug Metabolites, US Department of Health and Human, Services Food and Drug Administration, Center for Drug Evaluation and Research. Available from: http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0065-GDL.pdf [last accessed 20 Aug 2015]
- Zhu M, Zhao W, Vazquez N, Mitroka JG. (2005). Analysis of low level radioactive metabolites in biological fluids using high-performance liquid chromatography with microplate scintillation counting: method validation and application. J Pharma Biomed Anal 39:233–45